<

Zirgan (ganciclovir ophthalmic gel) 0.15%



ZIRGAN® (ganciclovir ophthalmic gel) 0.15% logo

Important Safety Information | Prescribing Information





REFERENCE MATERIALS


ZIRGAN prescribing information PDF

ZIRGAN Prescribing Information

ZIRGAN management of epithelial herpetic keratitis treatment algorithm PDF

Treatment Algorithm

ZIRGAN patient flipbook PDF

ZIRGAN Patient Flipbook


INDICATION

ZIRGAN (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).

IMPORTANT SAFETY INFORMATION

  • ZIRGAN is indicated for topical ophthalmic use only.

  • Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN.

  • Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).

  • Safety and efficacy in pediatric patients below the age of 2 years have not been established.

Click here for Prescribing Information about ZIRGAN.


Zirgan is a trademark of Laboratoires Théa Corporation used under license.

ZGN.0015.USA.17